Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug

MT Newswires Live

02/11

Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.

Shares gained about 3% in Wednesday's late morning trade.

F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.

The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.

The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.

Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610604468"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610604468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610604468?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610604468","market":"hk","top_or_hot":-1,"title":"Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug","media":"MT Newswires Live","content":"<html><body><p> Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.</p><p>Shares gained about 3% in Wednesday's late morning trade.</p><p>F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.</p><p>The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.</p><p>The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.</p><p>Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-11 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.</p><p>Shares gained about 3% in Wednesday's late morning trade.</p><p>F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.</p><p>The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.</p><p>The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.</p><p>Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IND.AU","symbol_name":"Industrial Minerals Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610604468","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610604468","pubTimestamp":1770782583,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Heron Neutron Medical  said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug  application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.Shares gained about 3% in Wednesday's late morning trade.F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IND.AU":"Industrial Minerals Ltd","IND":"Xtrackers Nifty 500 India ETF","BK7095":"多种金属与采矿"},"translate_title":"台湾FDA批准Heron Neutron Medical影像药物IND申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND.AU":1,"IND":1.5},"content_text":"Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.Shares gained about 3% in Wednesday's late morning trade.F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}